The US Food and Drug Administration last week told CombiMatrix that it can sell its Constitutional Genetic Analysis test through its CombiMatrix Molecular Diagnostics subsidiary without any additional regulatory evaluation.
But while CombiMatrix can now freely sell the CGAT, which uses array comparative genomic hybridization to test for a variety of genetic diseases, the company is not in the clear when it comes to the handful of tests it hopes to commercialize through CMDX over the next six months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.